Sera Prognostics Valuation Multiples

Sera Prognostics Overview

About Sera Prognostics

Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.

Founded

2008

HQ

Employees

64

Website

seraprognostics.com

Sectors

Medical DevicesDeepTechHealthTech

Financials (LTM)

Revenue: $150K

EBITDA: ($35M)

EV

$46M

Valuation Multiples

Multiples.vc

Start free trial

Sera Prognostics Financials

Sera Prognostics reported last 12-month revenue of $150K and negative EBITDA of ($35M).

In the same LTM period, Sera Prognostics generated ($83K) in gross profit, ($35M) in EBITDA losses, and had net loss of ($33M).

Sera Prognostics P&L

In the most recent fiscal year, Sera Prognostics reported revenue of $81K and EBITDA of ($31M).

Sera Prognostics expects next 12-month revenue of XXX and NTM EBITDA of XXX

Sera Prognostics Stock Performance

Sera Prognostics has current market cap of $83M, and enterprise value of $46M.

Sera Prognostics' stock price is $2.12.

Sera Prognostics Valuation Multiples

Sera Prognostics trades at 307.2x EV/Revenue multiple, and (1.3x) EV/EBITDA.

Sera Prognostics Financial Valuation Multiples

As of April 11, 2026, Sera Prognostics has market cap of $83M and EV of $46M.

Equity research analysts estimate Sera Prognostics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Sera Prognostics has a P/E ratio of (2.6x).

Sera Prognostics Margins & Growth Rates

Sera Prognostics' revenue in the last 12 month grew by 457%.

Sera Prognostics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.6M for the same period.

Sera Prognostics' rule of 40 is (9198%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Sera Prognostics' rule of X is (8731%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Sera Prognostics Public Comps

See public comps and valuation multiples for other Medical Devices comps.

Sera Prognostics M&A Activity

Sera Prognostics acquired XXX companies to date.

Last acquisition by Sera Prognostics was on XXXXXXXX, XXXXX. Sera Prognostics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Sera Prognostics Investment Activity

Sera Prognostics invested in XXX companies to date.

Sera Prognostics made its latest investment on XXXXXXXX, XXXXX. Sera Prognostics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).